Exact Sciences (EXAS) News Today

Exact Sciences (NASDAQ:EXAS) Stock Price Down 3%

CANADA LIFE ASSURANCE Co raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 5.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 207,364 shares of the medical research company's stock after acquiring an additional 10,356 share

Mitsubishi UFJ Trust & Banking Corp lowered its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 50.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 102,420 shares of the medical research company's st

Exact Sciences (NASDAQ:EXAS) will be releasing earnings after the market closes on Wednesday, July 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=606556)

Vanguard Group Inc. grew its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 1.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,740,092 shares of the medical research company's stock after buying an addi

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Investment analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Exact Sciences in a note issued to investors on Thursday, July 18th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earn

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 16.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,196 shares of the medical research company's

Blair William & Co. IL decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 6.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 346,869 shares of the medical research company's stock aft

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Exact Sciences in a research report issued on Thursday, July 18th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn

The Goldman Sachs Group cut their target price on shares of Exact Sciences from $88.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday.

Swiss National Bank decreased its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 541,580 shares of the medical research company's stock af

Susquehanna Fundamental Investments LLC increased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 257.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 186,358 shares of the medical research company's stock after buying an additional 134,2

Zevenbergen Capital Investments LLC boosted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 20.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,361,415 shares of the medical res

Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 14,210,000 shares, a growth of 50.4% from the June 15th total of 9,450,000 shares. Based on an average daily volume of 3,010,000 shares, the short-interest ratio is presently 4.7 days.

Grandfield & Dodd LLC grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 142.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,224 shares of the medic

Jennison Associates LLC lowered its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 53.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 633,629 shares of the medical researc

Baillie Gifford & Co. trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 54.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,701,988 shares of the medical research company's stock after

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 72.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 504,411 shares of the medica

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,973,592 shares of the medical research company's stock after sel

Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 9,450,000 shares, an increase of 7.6% from the May 31st total of 8,780,000 shares. Based on an average daily volume of 3,190,000 shares, the days-to-cover ratio is presently 3.0 days.

Evercore ISI decreased their price objective on Exact Sciences from $80.00 to $72.00 and set an "outperform" rating for the company in a research report on Tuesday.

Thompson Investment Management Inc. increased its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 13.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 160,584 shares of the medical research compan

Exact Sciences (NASDAQ:EXAS) Shares Gap Up to $41.37

BTIG Research lowered their target price on shares of Exact Sciences from $80.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday.

Exact Sciences (NASDAQ:EXAS) Hits New 52-Week Low at $40.91

Factory Mutual Insurance Co. lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 46.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,500 shares of the me

Exact Sciences (NASDAQ:EXAS) Shares Down 3.4%

Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Th

Vanguard Group Inc. lifted its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 0.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,559,751 shares of the medical research company's stock after buying an a

Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including

Exact Sciences (NASDAQ:EXAS) Hits New 52-Week Low at $41.17

Altitude Crest Partners Inc. acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 99,130 shares of the medical research company

Gabelli Funds LLC reduced its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 99.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,790 shares of the medical research company's stock aft

Bellevue Group AG decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,047,786 shares of the medical research company's stock after selling 72,033

Exact Sciences (NASDAQ:EXAS) Hits New 52-Week Low at $42.50

Campbell & CO Investment Adviser LLC cut its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 73.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,219 shares of the medical research company's